

CRISPR-Cas based diagnostic assay for Mycobacterium tuberculosis


Domain: Diagnostic (Assay/Kit)

About Technology: The present invention in general relates to assays and methods for the identification of Tuberculosis diseases. Particularly, the present invention relates to an in-vitro assay for the identification of Mycobacterium tuberculosis based on the CRISPR-Cas13a system

Intended Use: Detect Mycobacterium tuberculosis infections

Advantages:

- Rapid & Isothermal: Results in <3hour without thermal cycler
- Highly Specific & Sensitive: RNA-guided CRISPR detection
- Compatible with fluorescence or lateral flow readouts
- Potential for point-of-care use



IP Status: Filed (Indian Patent Application No.- 202311071943)

Technology Transfer Status: Transferred to a company on non-exclusive basis

Development Status: Third party validation complete

Institute(s): ICMR-National Institute for Research in Tuberculosis (NIRT)

Inventor(s): Dr.K.R.Uma Dev, P.Venkatesan

For Licensing Opportunities contact: patentmitra.hq@icmr.gov.in